SBIR/STTR Research Award

Incorporation of a biofilm dispersion autoinducer into an antimicrobial ointment for the treatment of topical wounds

Award identifier 60dccb181dbc8fb1393d47528ace9ad84974da6b3e6f42a999f5b27b09e11109Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$279,686

Program and phase

SBIR · Phase I

Award year

2018

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
EXCELSIOR BIOFILMS LLC
Proposal award date
2018-08-20
Contract end date
2019-07-31
UEI
CM6LTYJL7E95
Solicitation number
PA17-302
Topic code
NIAID

Research abstract

Project Summary Three species of biofilm forming bacteriaAcinetobacter baumanniiPseudomonas aeruginosa and Staphylococcus aureuswere recently identified by WHO as critical or high priority pathogens for which new antibiotics or antimicrobial treatments are urgently neededWe believe the inability to effectively prevent or treat a wide range of biofilm related chronic diseases may be overcome by using a biofilm dispersal signal as an adjunctive to conventional antimicrobial therapiesStudies in our laboratory have demonstrated that Paeruginosa produces a quorum sensing moleculecisdecenoic acidcis DAthat is responsible for autoinduction of the native dispersion response in biofilm bacteriaThis signaling molecule has been shown to induce a physiological change in bacteriacausing them to disaggregate from a biofilm and alter their physiologyrendering them more susceptible to antibioticsAdditionallycis DA has been shown to induce biofilm dispersion in a wide range of Gram negative and Gram positive bacteriaas well as fungiHere we propose to determine the degree to which cis DA can improve the anti biofilm activity of a petroleum jelly based ointment with embedded antimicrobialspolymyxin Bbacitracin and neomycinExperiments will examine the killing of preformed singleand multi species biofilmsAfter confirming that the cis DA adjunctive treatment is not toxic to human keratinocyteswe will test the effects on in vitro models of wounded and infected skinIn the final line of investigationwe will examine the efficacy and safety of the treatment in murine wound modelWe anticipate that this work will result in an antimicrobial anti biofilm formulation that will improve current treatment and prevention strategies against biofilm infections in topical wounds Project Narrative The current proposal is a request for funding to begin the early stage development of a novel adjunctive to antimicrobial treatment of biofilm infections caused by Acinetobacter baumanniiPseudomonas aeruginosaand Staphylococcus aureuspathogens for which newalternative antibiotic development has been identified as a critical or high priorityBy stimulating the innate biofilm dispersion responsethis adjunctive offers a unique and innovative antimicrobial strategy for enhancing the treatment of recalcitrant infections while generating minimal selective pressure for drug resistance

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.